· Venture Capital Tracker · investment-strategies · 2 min read
Astromech’s $20M at a Reported $3.8B: Biology-as-Weather Models
Bob Nelsen led Astromech’s $20M round — Colossal spinout claiming a $3.8B valuation on ~$60M total raised to forecast evolutionary change. The valuation is the story; commercial pilots are next.
VCT data record
Funding event facts
Source-backed financing and transaction details. Unknown terms remain undisclosed rather than estimated.
Astromech raises $20M led by Bob Nelsen at reported $3.8B valuation
Colossal spinout Astromech raised $20M led by Bob Nelsen to build evolutionary biology prediction models; SiliconANGLE reports $3.8B valuation and ~$60M total raised.
- Event type
- Funding Round
- Event date
- Aug 20, 2026
- Stage / label
- Venture
- Amount
- $20M
- Valuation
- $3.8B
- Confidence
- Reported
Company / target: Astromech
Lead: Bob Nelsen
Participants: Peak 6 , NeoGenesis Capital , Builders VC , CAZ Investments
Sources: siliconangle.com
Astromech, a Colossal Biosciences spinout from Ben Lamm and George Church, raised $20 million led by Bob Nelsen, bringing total capital to about $60 million and a reported $3.8 billion valuation (SiliconANGLE, August 20, 2026). Participants named: Peak 6, NeoGenesis Capital, Builders VC, CAZ Investments.
Spine / anomaly: ~$60M raised → $3.8B mark is a valuation event, not a commercial scale story. Diligence starts there.
Key facts
| Field | Detail |
|---|---|
| Company | Astromech (Colossal spinout; predictive biology models) |
| Round | $20M |
| Lead | Bob Nelsen (personally; ARCH co-founder) |
| Valuation (reported) | $3.8B |
| Total raised (reported) | ~$60M |
| Thesis | Forecast evolutionary / biological trajectories (“weather for biology”) |
| Near-term focus | Longevity gene mapping across species; biosecurity/health pilots |
Who would use the product — and for what job
Intended users: longevity researchers, biosecurity teams, and eventually drug/health partners who need hypothesis generation across species and deep time — not another protein-only foundation model.
Job: combine genomic + evolutionary + functional data to anticipate disease progression, resistance, and vulnerability — Church emphasizes ancestral regulatory states, not just ancestral proteins.
Why now
- Foundation-model capital is spilling into biology with extreme marks.
- Colossal’s public de-extinction brand creates distribution for spinout narratives.
- Longevity and biosecurity budgets are searching for differentiated datasets.
Why Nelsen — portfolio fit
Nelsen’s biotech track record is the signal: a specialist writing conviction into a platform biology bet. Founders likely wanted a biotech brand lead who underwrites decade-scale science risk — not a general AI fund chasing LLM comps.
Do not invent /fund/arch-venture-partners as the lead entity — SiliconANGLE attributes the lead to Bob Nelsen personally. Builders VC / others are not linked as /fund/ pages here.
Competitive map
| Player | Difference |
|---|---|
| Protein / molecule foundation model cos (e.g. Chai Discovery) | Different scientific object |
| Classical bioinformatics vendors | Weaker evolutionary deep-time framing |
| Colossal itself | Parent de-extinction ops vs predictive spinout IP |
What is not proven
- Any revenue, contracted pilots, or pharma LOIs in the cited piece.
- Whether $3.8B is primary round pricing vs secondary/mark-to-market storytelling.
- Predictive accuracy outside curated longevity gene maps (46 genes cited as mapped).
Practical takeaway
- Founders: If your mark is the headline, expect every diligence call to ask what $3.8B buys in validated forecasts.
- Investors: Separate science optionality from software SaaS multiples.
- Operators: Watch announced pilot partners — that is the next real data point.
Sources
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
